Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmaceutical and Clinical Research
Aritonang, Anggi Chatie Yunida
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
MEDICATION SAFETY PROFILE: A CASE REPORT OF FIRST TRIMESTER PREGNANCY PATIENTS WITH DEEP VEIN THROMBOSIS DIAGNOSIS ACCOMPANIED BY COMORBIDITY Aritonang, Anggi Chatie Yunida; Rambe, Rima Elfitra; Henny Sri Wahyuni; Lumbanraja, Sarma Nursani
Indonesian Journal of Pharmaceutical and Clinical Research Vol. 8 No. 02 (2025): Indonesian Journal of Pharmaceutical and Clinical Research
Publisher : Talenta Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/idjpcr.v8i02.21822

Abstract

Pregnancy is a hypercoagulable state that elevates the risk of Deep Vein Thrombosis (DVT). The selection of pharmacological interventions for DVT during pregnancy necessitates rigorous consideration of both maternal and fetal safety. Management becomes increasingly complex when the condition is accompanied by comorbidities, which often lead to polypharmacy and a higher potential for drug-drug interactions. This case report discusses a 33-year-old pregnant woman in her first trimester diagnosed with DVT in the left lower extremity, complicated by secondary hypertension, type 2 diabetes mellitus, and fever. The therapeutic regimen comprised 13 medications, including anticoagulants, antibiotics, analgesic-antipyretics, antiemetics, antihypertensives, and antidiabetic agents. Medication safety profiles were evaluated based on FDA pregnancy categories and other peer-reviewed references. Potential drug interactions were analyzed using the UpToDate® Lexicomp™ database. The study identified two drugs in category A, five in categories B and C, respectively, and one agent for which data was unavailable. Four potential drug interactions were identified, ranging from moderate to minor severity. All prescribed drugs demonstrated an adequate safety profile supported by current clinical literature. This study emphasizes the critical importance of a thorough risk-benefit analysis. Stringent monitoring is essential to ensure both the safety and efficacy of the treatment.
Co-Authors Henny Sri Wahyuni Rambe, Rima Elfitra Sarma Nursani Lumbanraja